New hope for Hard-to-Treat prostate cancer: targeted radiation plus chemo
Disease control
Not yet recruiting
This early-phase study tests a combination of chemotherapy (docetaxel) and a targeted radioactive drug (177Lu-PSMA) in 18 men with advanced prostate cancer that has stopped responding to hormone therapy. The main goal is to find the safest dose of docetaxel when given with the ra…
Phase: PHASE1 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated May 11, 2026 20:48 UTC